Latest News

Alzheimer’s Disease in Bilingual Latinos

Dr. Mirella Díaz-Santos, alongside her colleagues from UCLA Hispanic Neuropsychiatric Center of Excellence [HNCE], Dr. Paola Suarez (Co-Director of HNCE Cultural Neuropsychology Program) and Dr. Janet Yáñez (HNCE Fellow), recently published their work entitled, "Alzheimer’s Disease in Bilingual Latinos: Clinical Decisions for Diagnosis and Treatment Planning," on the Journal of Health Service Psychology. This paper highlights the heterogeneity in the clinical expression of Alzheimer’s disease among bilingual Latino/as, the clinical decisions leading to a culturally and linguistically congruent neuropsychological assessment, and the interdisciplinary, multi-setting partnerships needed to ensure a healthy longevity post-diagnosis for the patient, the caregiver, and the family.

For more information, visit:
Díaz-Santos, M., Yáñez, J. & Suarez, P.A. Alzheimer’s Disease in Bilingual Latinos: Clinical Decisions for Diagnosis and Treatment Planning. J Health Serv Psychol (2021). https://doi.org/10.1007/s42843-021-00050-5

Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

Dr. Keith Vossel, Professor of Neurology and Director of the UCLA Easton Center, published the highly anticipated results of a phase 2a randomized, placebo-controlled clinical trial of the anti-seizure medication levetiracetam for Alzheimer’s disease. This study was published in JAMA Neurology. The clinical trial showed that levetiracetam improves cognitive functions in Alzheimer’s patients with epileptic activity. The publication was featured in UCLA Health News and other news resources such as Newswise, Science Daily, News Medical, and more.  

New Research Suggests that Covid-19 Could Lead to Cognitive Decline

Dr. Keith Vossel, Professor of Neurology,and Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, David Geffen School of Medicine, was interviewed for a July 29th The Washington Post article suggesting that coronavirus infection may lead to cognitive decline.

What Is the New Alzheimer’s Disease Medication – and Who Should Get It?

Dr. Keith Vossel, Professor of Neurology, and Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, David Geffen School of Medicine, was featured in a June 15 UCLA Health article explaining the science behind the newly FDA approved Alzheimer's disease medication, Aduhelm (aducanumab).

The New Discovery of Inhibitors for the Treatment of Alzheimer's Disease

The Drug Discovery Lab, under the direction of Professor Varghese John, announced in the May 14, 2020 edition of UCLA Health news the publication in ACS Chemical Biology of their "... Discovery of a novel class of compounds that function as dual inhibitors of the enzymes neutral sphingomyelinase-2 (nSMase2) and acetylcholinesterase (AChE). Inhibition of these enzymes provides a unique strategy to suppress the propagation of tau pathology in the treatment of Alzheimer's disease (AD)." In the report, they describe the key structure-activity relationship elements that affect relative nSMase2 and/or AChE inhibitor effects and potency, as well as the identification of two compound analogs that suppress the release of tau-bearing exosomes in vitro and in vivo. Dr. John stated “Identification of these novel dual nSMase2/AChE inhibitors represents a new therapeutic approach to AD and has the potential to lead to the development of truly disease-modifying therapeutics." Read more in ACS Chemical Biology.

Health Professionals